NCT06490913View on ClinicalTrials.gov

Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Liver Metastases of Colorectal Cancer
Interventions
DRUG

Capecitabine

1000mg/m2, bid, d1-d14，q3w，1cycle

DRUG

oxaliplatin

130mg/m2, ivgtt, d1，q3w，1cycle

DRUG

Cetuximab

cetuximab 500mg/m2, q2w

DRUG

Oxaliplatin

85mg/m2, d1,q2w

DRUG

Leucovorin

400mg/m2, d1,q2w

DRUG

5-FU

400mg/m2，d1,q2w

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV

NCT06490913 - Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes | Biotech Hunter | Biotech Hunter